Emerging treatments

Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma. Ghai A et al. J Nucl Med. 2017 Oct 12. pii: jnumed.117.196063. doi: 10.2967/jnumed.117.196063. [Epub ahead of print]. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Kumar S et al. Blood. 2017 Oct 10. pii: blood-2017-06-788786. doi: 10.1182/blood-2017-06-788786. [Epub ahead of print]. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus…

Diagnostic techniques and prognostic indicators

Investigations of the Serum Free Light Chain Ratio According to the Updated 2014 IMWG Diagnostic Criteria for Multiple Myelomain Korean Patients with Newly Diagnosed Multiple Myeloma. Yang HS et al. Clin Lab. 2017 Oct 1;63(10):1765-1769. doi: 10.7754/Clin.Lab.2017.170341. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Iaccino E et al. Mol Cancer. 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8. Chromothripsis in Treatment Resistance in Multiple…

Current treatments

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Satin U et al. J Clin Apher. 2017 Oct 5. doi: 10.1002/jca.21591. [Epub ahead of print]. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Jeker B et al. Bone Marrow Transplant. 2017 Oct 23. doi: 10.1038/bmt.2017.234. [Epub ahead of print]. Phase II…

Complications of myeloma and its treatments

A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Cracolici V et al. Head Neck Pathol. 2017 Oct 13. doi: 10.1007/s12105-017-0861-7. [Epub ahead of print]. Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy. Nakae Y et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.9096-17. [Epub ahead of print].…

Biology and genetics

High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Sun Y et al. Cancer Lett. 2017 Oct 12. pii: S0304-3835(17)30629-8. doi: 10.1016/j.canlet.2017.10.005. [Epub ahead of print]. Characterization and use of the novel human multiple myelomacell line MC-b11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin a heavy chain. Walters DK et al. Exp Hematol. 2017 Oct 10. pii: S0301-472X(17)30814-7.…

Supportive treatments

Acupuncture for reduction of symptom burden in multiple myelomapatients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Deng G et al. Support Care Cancer. 2017 Sep 17. doi: 10.1007/s00520-017-3881-7. [Epub ahead of print]. The treatment of paraprotein-related kidney disease. Hutchison CA et al. Curr Opin Nephrol Hypertens. 2017 Sep 6. doi: 10.1097/MNH.0000000000000369. [Epub ahead of print]. Surgical Roles for Spinal…

General

Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Neelapu SS et al. Nat Rev Clin Oncol. 2017 Sep 19. doi: 10.1038/nrclinonc.2017.148. [Epub ahead of print]. Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma. Mikkilineni L et al. Blood. 2017 Sep 19. pii: blood-2017-06-793869. doi: 10.1182/blood-2017-06-793869. [Epub ahead of print]. Checking in: T cells against multiple myeloma. Kumar SK. Blood. 2017 Sep 7;130(10):1175-1176.…

Emerging Treatments

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. Hou J et al. Am J Clin Oncol. 2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print]. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Cavenagh J et al. Br J Cancer. 2017 Sep…

Diagnostic techniques and prognostic indicators

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Bhutani M et al. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6. Detection of Circulating Plasma Cells in Multiple Myeloma. Alix-Panabières C et al. Clin Chem. 2017 Sep 18. pii: clinchem.2017.275446. doi: 10.1373/clinchem.2017.275446. [Epub ahead of print]. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Sachpekidis C et al. Am J Nucl Med Mol Imaging. 2017 Sep…